We are excited to announce that preliminary data from our Phase 1 AMPLIFY-201 study of our cancer vaccine ELI-002 2P have been published in @NatureMedicine. Read more here: elicio.com/press_releases…
Elicio Therapeutics
@ElicioTx
Elicio (Nasdaq: $ELTX) is advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers.
Joined April 2021
